Prosecution Insights
Prosecution Insights
6 pending office actions • 3 art units • 3 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| §112 only | 3 (50%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 3 | 57.8% | +37.9% |
| COUNTS, GARY W | 2 | 58.9% | +29.3% |
| MCCOLLUM, ANDREA K | 1 | 60.7% | +32.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | SAOUD, CHRISTINE J | 88d overdue |
| 17131008 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | COUNTS, GARY W | 71d overdue |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | SAOUD, CHRISTINE J | 37d overdue |
| 16315805 | ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE | SAOUD, CHRISTINE J | 36d overdue |
| 17986255 | METHOD FOR PREDICTING THE RISK OF INCIDENCE OF CHRONIC KIDNEY DISEASE | MCCOLLUM, ANDREA K | 4d overdue |
| 17635265 | A METHOD FOR DIAGNOSING OR MONITORING KIDNEY FUNCTION OR DIAGNOSING KIDNEY DYSFUNCTION IN PEDIATRIC PATIENTS | COUNTS, GARY W | 56d |
| Art Unit | Apps |
|---|---|
| 1645 | 3 |
| 1678 | 2 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | SAOUD, CHRISTINE J | 1645 | §112 | Non-Final OA | 88d overdue | Pending | Dec 30, 2022 |
| 17986255 | METHOD FOR PREDICTING THE RISK OF INCIDENCE OF CHRONIC KIDNEY DISEASE | MCCOLLUM, ANDREA K | 1674 | Other | Non-Final OA | 4d overdue | Pending | Nov 14, 2022 |
| 17635265 | A METHOD FOR DIAGNOSING OR MONITORING KIDNEY FUNCTION OR DIAGNOSING KIDNEY DYSFUNCTION IN PEDIATRIC PATIENTS | COUNTS, GARY W | 1678 | §112 | Non-Final OA | 56d | Pending | Feb 14, 2022 |
| 17131008 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | COUNTS, GARY W | 1678 | §112 | Non-Final OA | 71d overdue | Pending | Dec 22, 2020 |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | SAOUD, CHRISTINE J | 1645 | §102 | Final Rejection | 37d overdue | Pending | Feb 04, 2020 |
| 16315805 | ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE | SAOUD, CHRISTINE J | 1645 | §103 | Non-Final OA | 36d overdue | Pending | Jan 07, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial